Renal Cell Carcinoma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
Not yet recruiting
  • Renal Cell Carcinoma
  • Neoadjuvant Lenvatinib
  • +3 more
  • (no location specified)
2022-03-31
Mar 31, 2022
O
Completed
  • Urothelial Carcinoma
  • +3 more
  • CT
  • Oslo, Norway
    Oslo University Hospital
2022-03-30
Mar 30, 2022
N
Enrolling by invitation
  • Adenocarcinoma
  • +4 more
  • EM Tracking
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
2022-04-07
Apr 7, 2022
H
Recruiting
  • Gastric Cancer
  • +8 more
  • Los Angeles, California
  • +2 more
2022-04-05
Apr 5, 2022
L
Recruiting
  • Renal Cell Carcinoma
  • Fecal Microbiota Transplantation
  • London, Ontario, Canada
    London Regional Cancer Program of the Lawson Health Research Ins
2022-04-05
Apr 5, 2022
N
Recruiting
  • Pancreatic Cancer
  • +15 more
  • Grand Rapids, Michigan
  • +2 more
2022-04-05
Apr 5, 2022
P
Withdrawn
  • Renal Cell Carcinoma
  • New York, New York
    Pfizer Inc.
2022-03-25
Mar 25, 2022
S
Recruiting
  • Kidney Cancer
  • +2 more
  • Doppler Ultrasound
  • Vantage 256 with C5-2v transducer
  • Stanford, California
    Stanford University School of Medicine
2022-03-25
Mar 25, 2022
P
Recruiting
  • Advanced Solid Tumor
  • +8 more
  • PY314
  • Combination Therapy: PY314 + Pembrolizumab
  • Scottsdale, Arizona
  • +12 more
2022-03-28
Mar 28, 2022
S
Completed
  • Acute Myeloid Leukemia
  • +8 more
  • DSP-7888 Dosing Emulsion
  • Denver, Colorado
  • +7 more
2022-04-04
Apr 4, 2022
N
Not yet recruiting
  • Pancreatic Cancer
  • +15 more
  • (no location specified)
2022-03-27
Mar 27, 2022
A
Recruiting
  • Advanced Solid Tumors With Literature Evidence of CD25(+) Treg Content
  • +12 more
  • Palo Alto, California
  • +9 more
2022-03-24
Mar 24, 2022
I
Active, not recruiting
  • Non-Small Cell Lung Cancer
  • +12 more
  • N-803 + Pembrolizumab
  • +9 more
  • Anchorage, Alaska
  • +34 more
2022-04-04
Apr 4, 2022
S
Withdrawn
  • Urologic Malignancies
  • +2 more
  • (no location specified)
2022-04-04
Apr 4, 2022
P
Recruiting
  • Breast Cancer
  • +8 more
  • Denver, Colorado
  • +1 more
2022-04-01
Apr 1, 2022
I
Active, not recruiting
  • Breast Cancer
  • Renal Cell Carcinoma
  • IPI-549 (eganelisib)
  • +3 more
  • Chandler, Arizona
  • +23 more
2022-04-01
Apr 1, 2022
S
Recruiting
  • Renal Cell Carcinoma
  • Metastatic Renal Cell Carcinoma
  • Doppler ultrasound
  • +2 more
  • Palo Alto, California
    Stanford
2022-03-22
Mar 22, 2022
M
Recruiting
  • Kidney Cancer
  • Renal Cell Carcinoma
  • New Brunswick, New Jersey
  • +2 more
2022-03-22
Mar 22, 2022
N
Recruiting
  • Renal Cell Carcinoma
  • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    2022-03-31
    Mar 31, 2022
    N
    Recruiting
    • Kidney Cancer
    • +4 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center, 9000 Rockville Pi
      2022-03-31
      Mar 31, 2022